Usage Patterns and Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Management: A Population-Based Study in Great Britain - Takeaways - MDSpire

Usage Patterns and Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Management: A Population-Based Study in Great Britain

  • By

  • Sarah E. Jackson

  • Jamie Brown

  • Clare Llewellyn

  • Oliver Mytton

  • Lion Shahab

  • January 8, 2026

  • 0 min

Share

  • 1

    Obesity in Great Britain poses significant public health challenges, increasing chronic disease risks and straining the NHS.

  • 2

    GLP-1 receptor agonists are effective for weight management and have cardio-protective effects, but long-term safety remains uncertain.

  • 3

    Public interest in GLP-1 medications is rising, with 22% of UK adults expressing willingness to use them if available on NHS prescription.

  • 4

    Gender differences influence GLP-1 medication demand, with women more likely to seek treatment due to higher obesity rates and societal pressures.

  • 5

    Equity of access to GLP-1 medications is a concern, as only 8% would use them privately, potentially exacerbating health inequalities.

Original Source(s)

Usage Patterns and Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Management: A Population-Based Study in Great Britain

  • by Sarah E. Jackson, Jamie Brown, Clare Llewellyn, Oliver Mytton, Lion Shahab

  • January 8, 2026

Related Content

Comparison of the association and discriminatory ability of CVAI, LAP, CI, and AVI for type 2 diabetes in Chinese adults aged ≥ 50 years: a sex-specific analysis

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.